Table I.
Percentage of activation (HLA-DR) and differentiation (CD27, CD28) markers, NKRs (CD94, NKG2A, NKG2C, CD158, NKG2D, and KLRG1), cytotoxic mediators (perforin and granzyme A), and chemokine receptor CX3CR1 on γδ T cells derived from CMV-infected and CMV-uninfected newborns
| Marker | CMV+ | CMV− | p (CMV+ versus CMV−) |
| HLA-DR+ | 6.34 (2.87–10.68) | 0.58 (0.27-0.80) | <0.0001 |
| CD27−CD28− | 43.82 (31.97–48.98) | 0.22 (0.13-0.45) | <0.0001 |
| CD94+ | 33.21 (23.68–57.20) | 4.44 (3.61-5.56) | <0.0001 |
| NKG2A+ | 10.99 (4.27–20.64) | 3.84 (2.33-5.11) | 0.0464 |
| NKG2C+ | 28.00 (10.77–35.54) | 1.17 (0.91–3.68) | <0.0001 |
| CD158a/h+ | 14.70 (6.61–30.53) | 1.56 (0.94–3.34) | <0.0001 |
| CD158b/j+ | 46.60 (29.07–51.38) | 2.75 (2.56–3.32) | <0.0001 |
| NKG2D+ | 69.18 (64.42–76.76) | 52.38 (46.26–63.08) | 0.0001 |
| KLRG1+ | 38.85 (27.80–45.41) | 24.70 (16.73–28.72) | 0.0009 |
| perforin+ | 61.50 (51.97–73.32) | 0.67 (0.48–1.77) | <0.0001 |
| granzyme A+ | 69.82 (57.97–79.63) | 4.38 (2.82–6.28) | <0.0001 |
| CX3CR1+ | 43.21 (25.08–57.96) | 1.11 (0.65–2.10) | 0.0003 |
Data for CMV+ and CMV− represent median (25–75% percentile). The gate is put on CD3+γδ+. CMV+, n = 8–18; CMV−, n = 9–22.